Abstract
Tetracyclines (TetraC) are widely used in dermatology for both inflammatory and infectious dermatoses; recently both in vivo and in vitro studies started to suggest also a potential antiviral effect. During COVID-19 outbreak, several dermatological patients contracted SARS-CoV-2 experiencing only mild symptoms, but no protocol were approved. A multicenter prospective observational study that enrolled COVID-19 patients visited with teledermatology and undergoing TetraC was performed. About 38 adult outpatients (M/F: 20/18, age 42.6 years [21-67]) were enrolled. During the TetraC treatment, symptoms resolved in all patients within 10 days. Remarkably, ageusia and anosmia disappeared in the first week of TetraC treatment. TetraC seem a promising drug to treat COVID-19 outpatients with mild symptoms.
Keywords: COVID-19; SARS-Cov-2; doxycycline; drug re-proposal; inflammatory dermatoses; minocycline; tetracyclines.
【저자키워드】 COVID-19, SARS-CoV-2, tetracyclines, doxycycline, Minocycline, drug re-proposal, inflammatory dermatoses, 【초록키워드】 Treatment, protocol, prospective observational study, Symptom, Antiviral effect, Anosmia, Ageusia, COVID-19 outbreak, Dermatology, Patient, age, multicenter, in vivo, mild symptoms, Inflammatory, COVID-19 patient, Tetracycline, in vitro study, treat, enrolled, approved, was performed, resolved, adult outpatient, COVID-19 outpatient, 【제목키워드】 real-world data, literature, Evidence, Inflammatory, COVID-19 patient, Tetracycline, multicenter observational study,